On March 28, 2018, Becton, Dickinson and Company (BDX) ended trading at a closing price of $212.43. The stock was trading at its 52-week high of $248.39 on January 29, 2018.
As of March 2018, BDX has fallen ~12.8%. The company reported strong 1Q18 results on February 6, 2018.
The highlights of the results of BDX’s fiscal 1Q18 are shown in the diagram above. For more details, read Becton Dickinson’s Fiscal 1Q18 Results Beat Analyst Estimates. The stock rose ~1.2% on the day. BDX reported its 52-week low of $175.66 on April 24, 2017. Currently, it’s trading below its 50-day moving average of $219.45 and higher than its 200-day moving average of $216.91.
In March 2018, BDX has been affected by global market weakness related to trade war fears triggered by the United States’ imposition of tariffs on Chinese imports. However, those fears have been allayed to some extent by reports of ongoing negotiations between the two countries as of late. On March 22, when President Donald Trump announced plans to impose tariffs on China, BDX fell ~2%.
Over the last 12 months, BDX has risen ~15.5%. In comparison, the broader market represented by the SPDR S&P 500 (SPY) and the US healthcare industry, which can be represented by the Healthcare Select Sector SPDR ETF (XLV), have registered one-year returns of 10% and 8.4%, respectively, as of March 29, 2018. Evidently, BDX has outperformed the healthcare industry and the broader market over the last year.
As of March 29, 2018, BDX’s peers Thermo Fisher Scientific (TMO), Abbott Laboratories (ABT), and Baxter (BAX) have registered 12-month returns of 34%, 33%, and 22%, respectively. This shows that BDX’s peers in the US medical technology space have outperformed it over the last year.